A Randomized, Partially Observer-Blind, Single-Centre Study to Evaluate Safety and Immunogenicity of MF59-Adjuvanted or Non-Adjuvanted H5N1 Influenza Vaccines in Adults Primed With Adjuvanted Influenza A/Vietnam/1194/04 (H5N1) Vaccine.

Trial Profile

A Randomized, Partially Observer-Blind, Single-Centre Study to Evaluate Safety and Immunogenicity of MF59-Adjuvanted or Non-Adjuvanted H5N1 Influenza Vaccines in Adults Primed With Adjuvanted Influenza A/Vietnam/1194/04 (H5N1) Vaccine.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; MF 59
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Jun 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 24 Jun 2012 United Kingdom Clinical Research Network reports accrual to date changed from 76 to 77%.
    • 30 Jul 2011 Planned end date changed from 30 Nov 2010 to 6 Jul 2011 as reported by UKCRN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top